Online citations, reference lists, and bibliographies.
← Back to Search

Valproic Acid Increases The Stimulatory Effect Of Estrogens On Proliferation Of Human Endometrial Adenocarcinoma Cells.

G. Graziani, L. Tentori, I. Portarena, M. Vergati, P. Navarra
Published 2003 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Long-term use of valproic acid (VA), a well-tolerated anticonvulsant agent widely used for treating epilepsia, has been recently shown to inhibit histone deacetylases, which in turn are involved in the regulation of the expression of estrogen receptor alpha (ERalpha) by suppressing gene transcription. Because estrogens are known to increase cell proliferation of human endometrial tumors, in this study we investigated whether treatment with VA may increase the proliferative response of human endometrial adenocarcinoma cells to 17-beta-estradiol through induction of ERalpha. The results clearly show that VA, at concentrations of clinical interest, significantly enhanced the proliferative activity exerted by 17-beta-estradiol in the endometrial adenocarcinoma Ishikawa cell line. Moreover, in these cells treatment with VA resulted in increased ERalpha gene expression. Similar effects of VA on cell proliferation were also observed in an ERalpha-positive breast cancer cell line (MCF-7). These findings indicate that VA might favor proliferation of estrogen-dependent human tumors.
This paper references
10.1101/GAD.14.1.55
Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression.
H. Kao (2000)
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.
A. T. Ferguson (1995)
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
V. Richon (2002)
10.1128/MCB.22.8.2463-2471.2002
Histone H1 Represses Estrogen Receptor α Transcriptional Activity by Selectively Inhibiting Receptor-Mediated Transcription Initiation
E. Cheung (2002)
10.1038/35106079
Histone deacetylases and cancer: causes and therapies
P. Marks (2001)
10.1056/NEJM199311043291904
Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy
J. I. Isojärvi (1993)
10.1210/ENDO.143.3.8694
CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway.
G. Graziani (2002)
10.1016/S1043-2760(01)00438-6
Histone deacetylase as a therapeutic target
O. Krämer (2001)
10.1046/j.1528-1157.2001.t01-1-28899.x
On the Association Between Valproate and Polycystic Ovary Syndrome: A Response and an Alternative View
J. Isojärvi (2001)
10.1074/JBC.M111871200
Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family*
Lin Gao (2002)
10.1007/s002800100322
Histone deacetylases and transcriptional therapy with their inhibitors
P. Pandolfi (2001)
Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
H. Huang (1999)
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
X. Yang (2000)
10.1074/JBC.M101287200
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*
C. Phiel (2001)
10.1002/ANA.410390506
Obesity and endocrine disorders in women taking valproate for epilepsy
Jouko I. T. Isojärvi (1996)
10.1016/S0092-8674(00)80211-1
What's Up and Down with Histone Deacetylation and Transcription?
M. Pazin (1997)
10.1038/417292a
A common mechanism of action for three mood-stabilizing drugs
R. S. Williams (2002)
10.1053/seiz.1999.0342
Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats
E. Taubøll (1999)
Histone deacetylase inhibitors as potential anti-skin cancer agents.
N. Saunders (1999)
10.1038/sj.onc.1204336
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
S. Minucci (2001)
10.1016/S0002-9343(01)00806-3
Altered ovarian function and cardiovascular risk factors in valproate-treated women.
J. Isojärvi (2001)
10.1073/PNAS.97.3.1056
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.
X. Zhou (2000)
10.1038/sj.cdd.4400832
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells
L. Tentori (2001)
10.1210/JCEM-63-2-356
Effects of estradiol on deoxyribonucleic acid polymerase alpha activity in the Ishikawa human endometrial adenocarcinoma cell line.
A. Gravanis (1986)
10.1016/S0304-3940(00)01559-7
A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: caspase-3 dependency
R. Li (2000)
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
V. Sandor (2002)
10.1016/S1097-2765(01)00429-4
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR.
W. Fischle (2002)
[Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors].
M. Nishida (1985)
10.1002/j.1460-2075.1988.tb03211.x
Genomic organization of the human oestrogen receptor gene.
M. Ponglikitmongkol (1988)
10.1093/emboj/20.24.6969
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M. Göttlicher (2001)
10.1016/S0303-7207(02)00011-4
Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells
A. Barsalou (2002)
10.1097/00001813-199711000-00007
Sodium valproate inhibits in vivo growth of human neuroblastoma cells.
J. Činátl (1997)
Suppression of histone deacetylation in vivo and in vitro by sodium butyrate.
L. Boffa (1978)
10.1055/S-2008-1043809
Valproic acid for the treatment of pediatric malignant glioma.
P. H. Driever (1999)
10.1016/S0006-8993(00)02797-9
Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain
T. O'Donnell (2000)
10.1097/00001813-200201000-00001
Histone deacetylase inhibitors in cancer treatment.
Vigushin Dm (2002)
10.1172/JCI11537
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
L. He (2001)
10.1097/00062752-200207000-00010
Histone deacetylases as therapeutic targets in hematologic malignancies.
A. Melnick (2002)
10.1016/S0145-2126(01)00151-5
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways.
R. Kawagoe (2002)
10.1006/BBRC.1999.0316
Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I.
J. Inokoshi (1999)
Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines.
A. deFazio (1992)
Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells
X. Yang (2001)
10.1006/EXCR.2000.5080
The human histone deacetylase family.
S. Gray (2001)
10.1074/JBC.274.49.34940
Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects*
L. Sambucetti (1999)
10.3892/IJO.20.1.97
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
J. Cinatl (2002)
Basic guide to the mechanisms of antiestrogen action.
J. I. MacGregor (1998)
10.1111/j.1528-1157.1992.tb02354.x
Effect of Antiepileptic Drugs on Growth of Murine Lymphoid Tumor Cells in Single‐Cell Culture
T. Tittle (1992)
10.1111/j.1749-6632.2001.tb03811.x
Role of Exogenous and Endogenous Hormones in Endometrial Cancer
A. Akhmedkhanov (2001)
10.1074/JBC.M908437199
mHDA1/HDAC5 Histone Deacetylase Interacts with and Represses MEF2A Transcriptional Activity*
C. Lemercier (2000)
10.1097/00001813-199609000-00008
Antitumor activity of sodium valproate in cultures of human neuroblastoma cells
J. Činátl (1996)



This paper is referenced by
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission.
G. Tringali (2004)
10.20944/preprints201703.0237.v1
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Anti-Proliferation Effects in Hepatocellular Carcinoma Cells
Subbroto Kumar Saha (2017)
10.1016/j.reprotox.2013.07.019
Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner.
Sandra Stempin (2013)
10.1677/ERC-08-0117
Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E.
H. Kashima (2009)
10.1016/J.AJOG.2004.05.025
The epigenetics of ovarian cancer drug resistance and resensitization.
C. Balch (2004)
Histon deasetilaz inhibitörü valproik asidin endometriyum hücrelerinde proliferasyon üzerine etkileri
Nurcan Tolun (2009)
Therapie du cancer et medicaments associes
C. Bunce (2005)
10.1093/molehr/gaq010
Epigenetic regulation of endometrium during the menstrual cycle.
S. Munro (2010)
10.1007/s10549-006-9459-6
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells
Leslie Hodges-Gallagher (2006)
10.3892/IJO_32_6_1293
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells.
F. Iacopino (2008)
10.1038/clpt.2012.141
Prenatal and Perinatal Environmental Influences on the Human Fetal and Placental Epigenome
Kirsten Hogg (2012)
10.1016/j.cnr.2004.09.013
Valproic acid: how it works. Or not
D. Lagace (2004)
Ácido Valpróico: revisão
Sayonara Beatriz (2008)
10.1007/s11064-008-9622-z
Regulation of ERα Signaling Pathway in Neuronal HN10 Cells: Role of Protein Acetylation and Hsp90
Tiina Suuronen (2008)
10.1093/toxsci/kfn219
The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol.
J. Naciff (2009)
10.1038/sj.bjc.6603156
Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
C. Cellai (2006)
10.17816/JOWD6837-14
Clinical features of polycystic ovary syndrome phenotypes in women with normogonadotropic anovulation in reproductive age
Elena I. Abashova (2019)
10.1517/13543784.13.1.21
Histone deacetylase inhibitors in clinical development
R. Rosato (2004)
10.1016/j.mce.2013.12.008
Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors
Han Fang Teng (2014)
10.3390/ijms18051048
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells
S. K. Saha (2017)
10.1124/MOL.105.014514
Opposite Effects of Histone Deacetylase Inhibitors on Glucocorticoid and Estrogen Signaling in Human Endometrial Ishikawa Cells
Walter Rocha (2005)
10.3892/ijo_00000262
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Tae Hyung Kim (2009)
10.21236/ada488263
Enhancing Hormonal Therapy for Breast Cancer by Combination with a Well-Known Approved Pharmaceutical with Little Toxicity
Peter J. Kushner (2008)
Valproic Acid : Review Ácido Valpróico : revisão Sayonara
B. Fagundes (2009)
Opposite effects of HDAC inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells
Walter Rocha (2005)
10.1002/MED.20027
Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies
R. Blaheta (2005)
Semantic Scholar Logo Some data provided by SemanticScholar